| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2146/AJHP090438 |
| P698 | PubMed publication ID | 19923317 |
| P2093 | author name string | Joanna Schwartz | |
| P2860 | cites work | Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. | Q36779175 |
| Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. | Q36830595 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Analysis of dermatologic events in patients with cancer treated with lapatinib. | Q37207083 | ||
| Lapatinib and ixabepilone for the treatment of metastatic breast cancer | Q37281586 | ||
| The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer | Q37378233 | ||
| Pooled analysis of diarrhea events in patients with cancer treated with lapatinib | Q46801526 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment | Q28255226 | ||
| Recommended guidelines for the treatment of cancer treatment-induced diarrhea | Q35836588 | ||
| Cutaneous side-effects of kinase inhibitors and blocking antibodies | Q36181698 | ||
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 | ||
| Management of hand-foot syndrome induced by capecitabine | Q36615314 | ||
| P433 | issue | 23 Suppl 6 | |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | S3-8 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Current combination chemotherapy regimens for metastatic breast cancer | |
| P478 | volume | 66 |
| Q35955198 | Combination drug delivery approaches in metastatic breast cancer |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q44244967 | Incidence-based cost-of-illness model for metastatic breast cancer in the United States. |
| Q39367399 | Polymeric micelles for multidrug delivery and combination therapy. |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q28285641 | RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity |
| Q34048144 | RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. |
| Q51362699 | Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine. |
Search more.